nodes	percent_of_prediction	percent_of_DWPC	metapath
Acamprosate—GRIN2D—prostate gland—prostate cancer	0.00719	0.144	CbGeAlD
Acamprosate—GRIN3B—testis—prostate cancer	0.00709	0.142	CbGeAlD
Acamprosate—SLC36A1—prostate gland—prostate cancer	0.00531	0.106	CbGeAlD
Acamprosate—GRM5—testis—prostate cancer	0.00447	0.0893	CbGeAlD
Acamprosate—SLC36A1—renal system—prostate cancer	0.00362	0.0723	CbGeAlD
Acamprosate—GRIN2C—testis—prostate cancer	0.00341	0.068	CbGeAlD
Acamprosate—GRIN2D—testis—prostate cancer	0.00317	0.0633	CbGeAlD
Acamprosate—GRIN3A—testis—prostate cancer	0.00298	0.0595	CbGeAlD
Acamprosate—SLC36A1—bone marrow—prostate cancer	0.00274	0.0546	CbGeAlD
Acamprosate—GABRB3—prostate gland—prostate cancer	0.00259	0.0516	CbGeAlD
Acamprosate—GRIN2A—testis—prostate cancer	0.00236	0.047	CbGeAlD
Acamprosate—SLC36A1—testis—prostate cancer	0.00234	0.0467	CbGeAlD
Acamprosate—SLC36A1—lymph node—prostate cancer	0.0017	0.0339	CbGeAlD
Acamprosate—GABRB3—testis—prostate cancer	0.00114	0.0227	CbGeAlD
Acamprosate—Skin disorder—Capecitabine—prostate cancer	0.000128	0.000192	CcSEcCtD
Acamprosate—Sweating—Doxorubicin—prostate cancer	0.000128	0.000191	CcSEcCtD
Acamprosate—Hyperhidrosis—Capecitabine—prostate cancer	0.000128	0.000191	CcSEcCtD
Acamprosate—Oedema peripheral—Epirubicin—prostate cancer	0.000128	0.000191	CcSEcCtD
Acamprosate—Hypotension—Docetaxel—prostate cancer	0.000127	0.000191	CcSEcCtD
Acamprosate—Haematuria—Doxorubicin—prostate cancer	0.000127	0.00019	CcSEcCtD
Acamprosate—Loss of consciousness—Prednisone—prostate cancer	0.000127	0.000189	CcSEcCtD
Acamprosate—Epistaxis—Doxorubicin—prostate cancer	0.000126	0.000188	CcSEcCtD
Acamprosate—Anorexia—Capecitabine—prostate cancer	0.000126	0.000188	CcSEcCtD
Acamprosate—Nausea—Estradiol—prostate cancer	0.000126	0.000188	CcSEcCtD
Acamprosate—Vomiting—Mitoxantrone—prostate cancer	0.000125	0.000188	CcSEcCtD
Acamprosate—Convulsion—Prednisone—prostate cancer	0.000125	0.000187	CcSEcCtD
Acamprosate—Visual impairment—Epirubicin—prostate cancer	0.000125	0.000187	CcSEcCtD
Acamprosate—Hypertension—Prednisone—prostate cancer	0.000124	0.000186	CcSEcCtD
Acamprosate—Rash—Mitoxantrone—prostate cancer	0.000124	0.000186	CcSEcCtD
Acamprosate—Dermatitis—Mitoxantrone—prostate cancer	0.000124	0.000186	CcSEcCtD
Acamprosate—Musculoskeletal discomfort—Docetaxel—prostate cancer	0.000124	0.000186	CcSEcCtD
Acamprosate—Headache—Mitoxantrone—prostate cancer	0.000124	0.000185	CcSEcCtD
Acamprosate—Hypotension—Capecitabine—prostate cancer	0.000123	0.000184	CcSEcCtD
Acamprosate—Insomnia—Docetaxel—prostate cancer	0.000123	0.000184	CcSEcCtD
Acamprosate—Arthralgia—Prednisone—prostate cancer	0.000123	0.000183	CcSEcCtD
Acamprosate—Myalgia—Prednisone—prostate cancer	0.000123	0.000183	CcSEcCtD
Acamprosate—Paraesthesia—Docetaxel—prostate cancer	0.000122	0.000183	CcSEcCtD
Acamprosate—Anxiety—Prednisone—prostate cancer	0.000122	0.000183	CcSEcCtD
Acamprosate—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	0.000122	0.000182	CcSEcCtD
Acamprosate—Dyspnoea—Docetaxel—prostate cancer	0.000122	0.000182	CcSEcCtD
Acamprosate—Somnolence—Docetaxel—prostate cancer	0.000121	0.000181	CcSEcCtD
Acamprosate—Discomfort—Prednisone—prostate cancer	0.000121	0.000181	CcSEcCtD
Acamprosate—Hypersensitivity—Etoposide—prostate cancer	0.000121	0.000181	CcSEcCtD
Acamprosate—Tinnitus—Epirubicin—prostate cancer	0.000121	0.000181	CcSEcCtD
Acamprosate—Haemoglobin—Doxorubicin—prostate cancer	0.00012	0.00018	CcSEcCtD
Acamprosate—Musculoskeletal discomfort—Capecitabine—prostate cancer	0.00012	0.00018	CcSEcCtD
Acamprosate—Rhinitis—Doxorubicin—prostate cancer	0.00012	0.00018	CcSEcCtD
Acamprosate—Dyspepsia—Docetaxel—prostate cancer	0.00012	0.00018	CcSEcCtD
Acamprosate—Haemorrhage—Doxorubicin—prostate cancer	0.00012	0.000179	CcSEcCtD
Acamprosate—Hepatitis—Doxorubicin—prostate cancer	0.00012	0.000179	CcSEcCtD
Acamprosate—Insomnia—Capecitabine—prostate cancer	0.000119	0.000179	CcSEcCtD
Acamprosate—Hypoaesthesia—Doxorubicin—prostate cancer	0.000119	0.000178	CcSEcCtD
Acamprosate—Pharyngitis—Doxorubicin—prostate cancer	0.000119	0.000178	CcSEcCtD
Acamprosate—Paraesthesia—Capecitabine—prostate cancer	0.000119	0.000177	CcSEcCtD
Acamprosate—Decreased appetite—Docetaxel—prostate cancer	0.000119	0.000177	CcSEcCtD
Acamprosate—Oedema peripheral—Doxorubicin—prostate cancer	0.000118	0.000176	CcSEcCtD
Acamprosate—Gastrointestinal disorder—Docetaxel—prostate cancer	0.000118	0.000176	CcSEcCtD
Acamprosate—Asthenia—Etoposide—prostate cancer	0.000118	0.000176	CcSEcCtD
Acamprosate—Dyspnoea—Capecitabine—prostate cancer	0.000118	0.000176	CcSEcCtD
Acamprosate—Anaphylactic shock—Prednisone—prostate cancer	0.000118	0.000176	CcSEcCtD
Acamprosate—Nausea—Mitoxantrone—prostate cancer	0.000117	0.000175	CcSEcCtD
Acamprosate—Immune system disorder—Epirubicin—prostate cancer	0.000117	0.000175	CcSEcCtD
Acamprosate—Infection—Prednisone—prostate cancer	0.000117	0.000175	CcSEcCtD
Acamprosate—Pain—Docetaxel—prostate cancer	0.000117	0.000174	CcSEcCtD
Acamprosate—Constipation—Docetaxel—prostate cancer	0.000117	0.000174	CcSEcCtD
Acamprosate—Dyspepsia—Capecitabine—prostate cancer	0.000116	0.000174	CcSEcCtD
Acamprosate—Chills—Epirubicin—prostate cancer	0.000116	0.000174	CcSEcCtD
Acamprosate—Pruritus—Etoposide—prostate cancer	0.000116	0.000174	CcSEcCtD
Acamprosate—Shock—Prednisone—prostate cancer	0.000116	0.000173	CcSEcCtD
Acamprosate—Visual impairment—Doxorubicin—prostate cancer	0.000115	0.000173	CcSEcCtD
Acamprosate—Tachycardia—Prednisone—prostate cancer	0.000115	0.000172	CcSEcCtD
Acamprosate—Decreased appetite—Capecitabine—prostate cancer	0.000115	0.000172	CcSEcCtD
Acamprosate—Alopecia—Epirubicin—prostate cancer	0.000114	0.000171	CcSEcCtD
Acamprosate—Skin disorder—Prednisone—prostate cancer	0.000114	0.000171	CcSEcCtD
Acamprosate—Gastrointestinal disorder—Capecitabine—prostate cancer	0.000114	0.00017	CcSEcCtD
Acamprosate—Hyperhidrosis—Prednisone—prostate cancer	0.000114	0.00017	CcSEcCtD
Acamprosate—Mental disorder—Epirubicin—prostate cancer	0.000113	0.00017	CcSEcCtD
Acamprosate—Constipation—Capecitabine—prostate cancer	0.000113	0.000169	CcSEcCtD
Acamprosate—Pain—Capecitabine—prostate cancer	0.000113	0.000169	CcSEcCtD
Acamprosate—Malnutrition—Epirubicin—prostate cancer	0.000113	0.000169	CcSEcCtD
Acamprosate—Feeling abnormal—Docetaxel—prostate cancer	0.000112	0.000168	CcSEcCtD
Acamprosate—Diarrhoea—Etoposide—prostate cancer	0.000112	0.000168	CcSEcCtD
Acamprosate—Anorexia—Prednisone—prostate cancer	0.000112	0.000168	CcSEcCtD
Acamprosate—Tinnitus—Doxorubicin—prostate cancer	0.000112	0.000167	CcSEcCtD
Acamprosate—Gastrointestinal pain—Docetaxel—prostate cancer	0.000112	0.000167	CcSEcCtD
Acamprosate—Flatulence—Epirubicin—prostate cancer	0.000111	0.000166	CcSEcCtD
Acamprosate—Tension—Epirubicin—prostate cancer	0.000111	0.000165	CcSEcCtD
Acamprosate—Dysgeusia—Epirubicin—prostate cancer	0.00011	0.000165	CcSEcCtD
Acamprosate—Nervousness—Epirubicin—prostate cancer	0.000109	0.000164	CcSEcCtD
Acamprosate—Back pain—Epirubicin—prostate cancer	0.000109	0.000163	CcSEcCtD
Acamprosate—Feeling abnormal—Capecitabine—prostate cancer	0.000109	0.000163	CcSEcCtD
Acamprosate—Dizziness—Etoposide—prostate cancer	0.000109	0.000162	CcSEcCtD
Acamprosate—Muscle spasms—Epirubicin—prostate cancer	0.000108	0.000162	CcSEcCtD
Acamprosate—Immune system disorder—Doxorubicin—prostate cancer	0.000108	0.000162	CcSEcCtD
Acamprosate—Gastrointestinal pain—Capecitabine—prostate cancer	0.000108	0.000161	CcSEcCtD
Acamprosate—Body temperature increased—Docetaxel—prostate cancer	0.000108	0.000161	CcSEcCtD
Acamprosate—Abdominal pain—Docetaxel—prostate cancer	0.000108	0.000161	CcSEcCtD
Acamprosate—GABRG2—Transmembrane transport of small molecules—SLC22A3—prostate cancer	0.000108	0.000383	CbGpPWpGaD
Acamprosate—Chills—Doxorubicin—prostate cancer	0.000108	0.000161	CcSEcCtD
Acamprosate—Musculoskeletal discomfort—Prednisone—prostate cancer	0.000107	0.00016	CcSEcCtD
Acamprosate—Insomnia—Prednisone—prostate cancer	0.000106	0.000159	CcSEcCtD
Acamprosate—Alopecia—Doxorubicin—prostate cancer	0.000106	0.000158	CcSEcCtD
Acamprosate—Paraesthesia—Prednisone—prostate cancer	0.000106	0.000158	CcSEcCtD
Acamprosate—GRIN1—BDNF signaling pathway—SRC—prostate cancer	0.000105	0.000374	CbGpPWpGaD
Acamprosate—Mental disorder—Doxorubicin—prostate cancer	0.000105	0.000157	CcSEcCtD
Acamprosate—Urticaria—Capecitabine—prostate cancer	0.000105	0.000157	CcSEcCtD
Acamprosate—Ill-defined disorder—Epirubicin—prostate cancer	0.000105	0.000156	CcSEcCtD
Acamprosate—Body temperature increased—Capecitabine—prostate cancer	0.000104	0.000156	CcSEcCtD
Acamprosate—Abdominal pain—Capecitabine—prostate cancer	0.000104	0.000156	CcSEcCtD
Acamprosate—Vomiting—Etoposide—prostate cancer	0.000104	0.000156	CcSEcCtD
Acamprosate—Malnutrition—Doxorubicin—prostate cancer	0.000104	0.000156	CcSEcCtD
Acamprosate—Anaemia—Epirubicin—prostate cancer	0.000104	0.000156	CcSEcCtD
Acamprosate—GRIN1—Transmission across Chemical Synapses—MDM2—prostate cancer	0.000104	0.000369	CbGpPWpGaD
Acamprosate—GRIN1—Developmental Biology—PRKCQ—prostate cancer	0.000104	0.000369	CbGpPWpGaD
Acamprosate—Agitation—Epirubicin—prostate cancer	0.000104	0.000155	CcSEcCtD
Acamprosate—Dyspepsia—Prednisone—prostate cancer	0.000104	0.000155	CcSEcCtD
Acamprosate—Rash—Etoposide—prostate cancer	0.000103	0.000155	CcSEcCtD
Acamprosate—Dermatitis—Etoposide—prostate cancer	0.000103	0.000155	CcSEcCtD
Acamprosate—GABRA1—SIDS Susceptibility Pathways—HIF1A—prostate cancer	0.000103	0.000368	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—PTHLH—prostate cancer	0.000103	0.000367	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—TGFBR1—prostate cancer	0.000103	0.000367	CbGpPWpGaD
Acamprosate—Headache—Etoposide—prostate cancer	0.000103	0.000154	CcSEcCtD
Acamprosate—Flatulence—Doxorubicin—prostate cancer	0.000103	0.000154	CcSEcCtD
Acamprosate—GRIN1—Developmental Biology—NCOA1—prostate cancer	0.000103	0.000366	CbGpPWpGaD
Acamprosate—GRIN2B—BDNF signaling pathway—SRC—prostate cancer	0.000103	0.000365	CbGpPWpGaD
Acamprosate—Tension—Doxorubicin—prostate cancer	0.000102	0.000153	CcSEcCtD
Acamprosate—Decreased appetite—Prednisone—prostate cancer	0.000102	0.000153	CcSEcCtD
Acamprosate—Dysgeusia—Doxorubicin—prostate cancer	0.000102	0.000153	CcSEcCtD
Acamprosate—Malaise—Epirubicin—prostate cancer	0.000102	0.000152	CcSEcCtD
Acamprosate—GRIN1—SIDS Susceptibility Pathways—EP300—prostate cancer	0.000102	0.000361	CbGpPWpGaD
Acamprosate—GRIN1—BDNF signaling pathway—STAT3—prostate cancer	0.000101	0.000361	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—AKR1C3—prostate cancer	0.000101	0.000361	CbGpPWpGaD
Acamprosate—Nervousness—Doxorubicin—prostate cancer	0.000101	0.000151	CcSEcCtD
Acamprosate—Vertigo—Epirubicin—prostate cancer	0.000101	0.000151	CcSEcCtD
Acamprosate—GRIN2B—Transmission across Chemical Synapses—MDM2—prostate cancer	0.000101	0.00036	CbGpPWpGaD
Acamprosate—GABRB3—Transmembrane transport of small molecules—ABCG5—prostate cancer	0.000101	0.00036	CbGpPWpGaD
Acamprosate—Syncope—Epirubicin—prostate cancer	0.000101	0.000151	CcSEcCtD
Acamprosate—GRIN2B—Developmental Biology—PRKCQ—prostate cancer	0.000101	0.00036	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—PRKACB—prostate cancer	0.000101	0.000359	CbGpPWpGaD
Acamprosate—Leukopenia—Epirubicin—prostate cancer	0.000101	0.000151	CcSEcCtD
Acamprosate—Back pain—Doxorubicin—prostate cancer	0.000101	0.000151	CcSEcCtD
Acamprosate—Constipation—Prednisone—prostate cancer	0.000101	0.00015	CcSEcCtD
Acamprosate—Hypersensitivity—Docetaxel—prostate cancer	0.0001	0.00015	CcSEcCtD
Acamprosate—Muscle spasms—Doxorubicin—prostate cancer	0.0001	0.00015	CcSEcCtD
Acamprosate—GRIN2B—Developmental Biology—NCOA1—prostate cancer	0.0001	0.000356	CbGpPWpGaD
Acamprosate—GABRB3—BDNF signaling pathway—MAP2K1—prostate cancer	0.0001	0.000356	CbGpPWpGaD
Acamprosate—Palpitations—Epirubicin—prostate cancer	9.96e-05	0.000149	CcSEcCtD
Acamprosate—GABRG2—Transmembrane transport of small molecules—ABCG5—prostate cancer	9.93e-05	0.000353	CbGpPWpGaD
Acamprosate—Loss of consciousness—Epirubicin—prostate cancer	9.91e-05	0.000148	CcSEcCtD
Acamprosate—GRIN2B—BDNF signaling pathway—STAT3—prostate cancer	9.89e-05	0.000352	CbGpPWpGaD
Acamprosate—GRIN1—Developmental Biology—FGF10—prostate cancer	9.85e-05	0.00035	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—PPP3CA—prostate cancer	9.84e-05	0.00035	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—THBS1—prostate cancer	9.84e-05	0.00035	CbGpPWpGaD
Acamprosate—Cough—Epirubicin—prostate cancer	9.84e-05	0.000147	CcSEcCtD
Acamprosate—GABRB3—Neuronal System—COMT—prostate cancer	9.81e-05	0.000349	CbGpPWpGaD
Acamprosate—Asthenia—Docetaxel—prostate cancer	9.79e-05	0.000146	CcSEcCtD
Acamprosate—GRIN1—Developmental Biology—RXRA—prostate cancer	9.77e-05	0.000348	CbGpPWpGaD
Acamprosate—Convulsion—Epirubicin—prostate cancer	9.77e-05	0.000146	CcSEcCtD
Acamprosate—Nausea—Etoposide—prostate cancer	9.75e-05	0.000146	CcSEcCtD
Acamprosate—Hypertension—Epirubicin—prostate cancer	9.73e-05	0.000146	CcSEcCtD
Acamprosate—Hypersensitivity—Capecitabine—prostate cancer	9.73e-05	0.000145	CcSEcCtD
Acamprosate—GRIN1—Axon guidance—KDR—prostate cancer	9.73e-05	0.000346	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—ANXA1—prostate cancer	9.7e-05	0.000345	CbGpPWpGaD
Acamprosate—Feeling abnormal—Prednisone—prostate cancer	9.69e-05	0.000145	CcSEcCtD
Acamprosate—Ill-defined disorder—Doxorubicin—prostate cancer	9.68e-05	0.000145	CcSEcCtD
Acamprosate—Pruritus—Docetaxel—prostate cancer	9.65e-05	0.000144	CcSEcCtD
Acamprosate—Anaemia—Doxorubicin—prostate cancer	9.64e-05	0.000144	CcSEcCtD
Acamprosate—GABRG2—Neuronal System—COMT—prostate cancer	9.63e-05	0.000343	CbGpPWpGaD
Acamprosate—Gastrointestinal pain—Prednisone—prostate cancer	9.62e-05	0.000144	CcSEcCtD
Acamprosate—GRIN1—SIDS Susceptibility Pathways—VEGFA—prostate cancer	9.61e-05	0.000342	CbGpPWpGaD
Acamprosate—GRIN2B—Developmental Biology—FGF10—prostate cancer	9.6e-05	0.000342	CbGpPWpGaD
Acamprosate—Chest pain—Epirubicin—prostate cancer	9.6e-05	0.000143	CcSEcCtD
Acamprosate—Myalgia—Epirubicin—prostate cancer	9.6e-05	0.000143	CcSEcCtD
Acamprosate—Arthralgia—Epirubicin—prostate cancer	9.6e-05	0.000143	CcSEcCtD
Acamprosate—Agitation—Doxorubicin—prostate cancer	9.58e-05	0.000143	CcSEcCtD
Acamprosate—Anxiety—Epirubicin—prostate cancer	9.56e-05	0.000143	CcSEcCtD
Acamprosate—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	9.53e-05	0.000143	CcSEcCtD
Acamprosate—GRIN2B—Developmental Biology—RXRA—prostate cancer	9.53e-05	0.000339	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—PRKCZ—prostate cancer	9.52e-05	0.000339	CbGpPWpGaD
Acamprosate—GRIN1—Developmental Biology—VAV3—prostate cancer	9.5e-05	0.000338	CbGpPWpGaD
Acamprosate—Discomfort—Epirubicin—prostate cancer	9.48e-05	0.000142	CcSEcCtD
Acamprosate—GRIN2B—Axon guidance—KDR—prostate cancer	9.48e-05	0.000337	CbGpPWpGaD
Acamprosate—Asthenia—Capecitabine—prostate cancer	9.47e-05	0.000142	CcSEcCtD
Acamprosate—Malaise—Doxorubicin—prostate cancer	9.41e-05	0.000141	CcSEcCtD
Acamprosate—GABRA1—Transmembrane transport of small molecules—SLC22A3—prostate cancer	9.4e-05	0.000335	CbGpPWpGaD
Acamprosate—Dry mouth—Epirubicin—prostate cancer	9.39e-05	0.00014	CcSEcCtD
Acamprosate—Vertigo—Doxorubicin—prostate cancer	9.37e-05	0.00014	CcSEcCtD
Acamprosate—Syncope—Doxorubicin—prostate cancer	9.35e-05	0.00014	CcSEcCtD
Acamprosate—Urticaria—Prednisone—prostate cancer	9.34e-05	0.00014	CcSEcCtD
Acamprosate—Pruritus—Capecitabine—prostate cancer	9.34e-05	0.00014	CcSEcCtD
Acamprosate—Leukopenia—Doxorubicin—prostate cancer	9.34e-05	0.00014	CcSEcCtD
Acamprosate—Diarrhoea—Docetaxel—prostate cancer	9.33e-05	0.00014	CcSEcCtD
Acamprosate—GRM5—GPCR downstream signaling—PIK3CG—prostate cancer	9.3e-05	0.000331	CbGpPWpGaD
Acamprosate—Body temperature increased—Prednisone—prostate cancer	9.3e-05	0.000139	CcSEcCtD
Acamprosate—Abdominal pain—Prednisone—prostate cancer	9.3e-05	0.000139	CcSEcCtD
Acamprosate—Confusional state—Epirubicin—prostate cancer	9.28e-05	0.000139	CcSEcCtD
Acamprosate—GRIN2B—Developmental Biology—VAV3—prostate cancer	9.27e-05	0.00033	CbGpPWpGaD
Acamprosate—Palpitations—Doxorubicin—prostate cancer	9.22e-05	0.000138	CcSEcCtD
Acamprosate—Anaphylactic shock—Epirubicin—prostate cancer	9.2e-05	0.000138	CcSEcCtD
Acamprosate—GRM5—Signaling Pathways—FGFR4—prostate cancer	9.19e-05	0.000327	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—PARP1—prostate cancer	9.19e-05	0.000327	CbGpPWpGaD
Acamprosate—Loss of consciousness—Doxorubicin—prostate cancer	9.17e-05	0.000137	CcSEcCtD
Acamprosate—Infection—Epirubicin—prostate cancer	9.14e-05	0.000137	CcSEcCtD
Acamprosate—GABRB3—BDNF signaling pathway—JAK2—prostate cancer	9.12e-05	0.000325	CbGpPWpGaD
Acamprosate—GRIN2A—Neuronal System—MDM2—prostate cancer	9.12e-05	0.000324	CbGpPWpGaD
Acamprosate—GABRB3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—prostate cancer	9.11e-05	0.000324	CbGpPWpGaD
Acamprosate—Cough—Doxorubicin—prostate cancer	9.1e-05	0.000136	CcSEcCtD
Acamprosate—GRIN1—Spinal Cord Injury—TP53—prostate cancer	9.08e-05	0.000323	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—CALCA—prostate cancer	9.08e-05	0.000323	CbGpPWpGaD
Acamprosate—Shock—Epirubicin—prostate cancer	9.05e-05	0.000135	CcSEcCtD
Acamprosate—Convulsion—Doxorubicin—prostate cancer	9.04e-05	0.000135	CcSEcCtD
Acamprosate—Diarrhoea—Capecitabine—prostate cancer	9.04e-05	0.000135	CcSEcCtD
Acamprosate—Dizziness—Docetaxel—prostate cancer	9.02e-05	0.000135	CcSEcCtD
Acamprosate—Thrombocytopenia—Epirubicin—prostate cancer	9.01e-05	0.000135	CcSEcCtD
Acamprosate—Hypertension—Doxorubicin—prostate cancer	9e-05	0.000135	CcSEcCtD
Acamprosate—Tachycardia—Epirubicin—prostate cancer	8.98e-05	0.000134	CcSEcCtD
Acamprosate—SLC36A1—Transmembrane transport of small molecules—CREBBP—prostate cancer	8.96e-05	0.000319	CbGpPWpGaD
Acamprosate—GABRG2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—prostate cancer	8.94e-05	0.000318	CbGpPWpGaD
Acamprosate—Skin disorder—Epirubicin—prostate cancer	8.94e-05	0.000134	CcSEcCtD
Acamprosate—GABRB3—Transmembrane transport of small molecules—SLC22A1—prostate cancer	8.93e-05	0.000318	CbGpPWpGaD
Acamprosate—Hyperhidrosis—Epirubicin—prostate cancer	8.89e-05	0.000133	CcSEcCtD
Acamprosate—Arthralgia—Doxorubicin—prostate cancer	8.88e-05	0.000133	CcSEcCtD
Acamprosate—Myalgia—Doxorubicin—prostate cancer	8.88e-05	0.000133	CcSEcCtD
Acamprosate—Chest pain—Doxorubicin—prostate cancer	8.88e-05	0.000133	CcSEcCtD
Acamprosate—GRM5—Signaling Pathways—CXCL12—prostate cancer	8.87e-05	0.000316	CbGpPWpGaD
Acamprosate—Anxiety—Doxorubicin—prostate cancer	8.85e-05	0.000132	CcSEcCtD
Acamprosate—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	8.82e-05	0.000132	CcSEcCtD
Acamprosate—Discomfort—Doxorubicin—prostate cancer	8.77e-05	0.000131	CcSEcCtD
Acamprosate—GABRG2—Transmembrane transport of small molecules—SLC22A1—prostate cancer	8.77e-05	0.000312	CbGpPWpGaD
Acamprosate—Anorexia—Epirubicin—prostate cancer	8.77e-05	0.000131	CcSEcCtD
Acamprosate—Dizziness—Capecitabine—prostate cancer	8.73e-05	0.000131	CcSEcCtD
Acamprosate—Dry mouth—Doxorubicin—prostate cancer	8.68e-05	0.00013	CcSEcCtD
Acamprosate—GABRA1—Transmembrane transport of small molecules—ABCG5—prostate cancer	8.68e-05	0.000309	CbGpPWpGaD
Acamprosate—Vomiting—Docetaxel—prostate cancer	8.67e-05	0.00013	CcSEcCtD
Acamprosate—Hypersensitivity—Prednisone—prostate cancer	8.67e-05	0.00013	CcSEcCtD
Acamprosate—Rash—Docetaxel—prostate cancer	8.6e-05	0.000129	CcSEcCtD
Acamprosate—GRIN1—Axon guidance—GSK3B—prostate cancer	8.6e-05	0.000306	CbGpPWpGaD
Acamprosate—Hypotension—Epirubicin—prostate cancer	8.6e-05	0.000129	CcSEcCtD
Acamprosate—Dermatitis—Docetaxel—prostate cancer	8.59e-05	0.000128	CcSEcCtD
Acamprosate—Confusional state—Doxorubicin—prostate cancer	8.58e-05	0.000128	CcSEcCtD
Acamprosate—Headache—Docetaxel—prostate cancer	8.54e-05	0.000128	CcSEcCtD
Acamprosate—Anaphylactic shock—Doxorubicin—prostate cancer	8.51e-05	0.000127	CcSEcCtD
Acamprosate—GABRB3—Transmembrane transport of small molecules—GNG5—prostate cancer	8.5e-05	0.000302	CbGpPWpGaD
Acamprosate—Infection—Doxorubicin—prostate cancer	8.46e-05	0.000126	CcSEcCtD
Acamprosate—GRIN1—Developmental Biology—LPL—prostate cancer	8.45e-05	0.000301	CbGpPWpGaD
Acamprosate—GRM5—Signaling by GPCR—PIK3CG—prostate cancer	8.45e-05	0.000301	CbGpPWpGaD
Acamprosate—GABRA1—SIDS Susceptibility Pathways—CREBBP—prostate cancer	8.44e-05	0.0003	CbGpPWpGaD
Acamprosate—Asthenia—Prednisone—prostate cancer	8.44e-05	0.000126	CcSEcCtD
Acamprosate—GABRA1—Neuronal System—COMT—prostate cancer	8.42e-05	0.0003	CbGpPWpGaD
Acamprosate—Vomiting—Capecitabine—prostate cancer	8.4e-05	0.000126	CcSEcCtD
Acamprosate—Musculoskeletal discomfort—Epirubicin—prostate cancer	8.38e-05	0.000125	CcSEcCtD
Acamprosate—GRIN2B—Axon guidance—GSK3B—prostate cancer	8.38e-05	0.000298	CbGpPWpGaD
Acamprosate—Shock—Doxorubicin—prostate cancer	8.37e-05	0.000125	CcSEcCtD
Acamprosate—GRM5—Signaling Pathways—CASP9—prostate cancer	8.35e-05	0.000297	CbGpPWpGaD
Acamprosate—GABRG2—Transmembrane transport of small molecules—GNG5—prostate cancer	8.34e-05	0.000297	CbGpPWpGaD
Acamprosate—Thrombocytopenia—Doxorubicin—prostate cancer	8.33e-05	0.000125	CcSEcCtD
Acamprosate—Rash—Capecitabine—prostate cancer	8.33e-05	0.000124	CcSEcCtD
Acamprosate—Pruritus—Prednisone—prostate cancer	8.32e-05	0.000124	CcSEcCtD
Acamprosate—Insomnia—Epirubicin—prostate cancer	8.32e-05	0.000124	CcSEcCtD
Acamprosate—Dermatitis—Capecitabine—prostate cancer	8.32e-05	0.000124	CcSEcCtD
Acamprosate—GRIN1—Spinal Cord Injury—IL6—prostate cancer	8.31e-05	0.000296	CbGpPWpGaD
Acamprosate—Tachycardia—Doxorubicin—prostate cancer	8.31e-05	0.000124	CcSEcCtD
Acamprosate—Headache—Capecitabine—prostate cancer	8.27e-05	0.000124	CcSEcCtD
Acamprosate—Skin disorder—Doxorubicin—prostate cancer	8.27e-05	0.000124	CcSEcCtD
Acamprosate—Paraesthesia—Epirubicin—prostate cancer	8.26e-05	0.000124	CcSEcCtD
Acamprosate—GRIN2B—Developmental Biology—LPL—prostate cancer	8.24e-05	0.000293	CbGpPWpGaD
Acamprosate—Hyperhidrosis—Doxorubicin—prostate cancer	8.23e-05	0.000123	CcSEcCtD
Acamprosate—Dyspnoea—Epirubicin—prostate cancer	8.2e-05	0.000123	CcSEcCtD
Acamprosate—GRM5—GPCR downstream signaling—PIK3CD—prostate cancer	8.18e-05	0.000291	CbGpPWpGaD
Acamprosate—Somnolence—Epirubicin—prostate cancer	8.18e-05	0.000122	CcSEcCtD
Acamprosate—GRIN1—Developmental Biology—ITGB3—prostate cancer	8.16e-05	0.00029	CbGpPWpGaD
Acamprosate—Anorexia—Doxorubicin—prostate cancer	8.11e-05	0.000121	CcSEcCtD
Acamprosate—Nausea—Docetaxel—prostate cancer	8.1e-05	0.000121	CcSEcCtD
Acamprosate—Dyspepsia—Epirubicin—prostate cancer	8.1e-05	0.000121	CcSEcCtD
Acamprosate—GRM5—Signaling Pathways—NGFR—prostate cancer	8.09e-05	0.000288	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—PRKCQ—prostate cancer	8.09e-05	0.000288	CbGpPWpGaD
Acamprosate—Diarrhoea—Prednisone—prostate cancer	8.05e-05	0.00012	CcSEcCtD
Acamprosate—GRM5—Signaling Pathways—MAP3K7—prostate cancer	8e-05	0.000285	CbGpPWpGaD
Acamprosate—Decreased appetite—Epirubicin—prostate cancer	8e-05	0.00012	CcSEcCtD
Acamprosate—GABRB3—BDNF signaling pathway—CASP3—prostate cancer	7.97e-05	0.000284	CbGpPWpGaD
Acamprosate—GRIN2B—Developmental Biology—ITGB3—prostate cancer	7.96e-05	0.000283	CbGpPWpGaD
Acamprosate—Hypotension—Doxorubicin—prostate cancer	7.95e-05	0.000119	CcSEcCtD
Acamprosate—GRIN1—Neuronal System—MDM2—prostate cancer	7.95e-05	0.000283	CbGpPWpGaD
Acamprosate—Gastrointestinal disorder—Epirubicin—prostate cancer	7.94e-05	0.000119	CcSEcCtD
Acamprosate—GRIN1—Axon guidance—MMP2—prostate cancer	7.94e-05	0.000282	CbGpPWpGaD
Acamprosate—GRIN1—Axon guidance—MAP2K1—prostate cancer	7.93e-05	0.000282	CbGpPWpGaD
Acamprosate—Pain—Epirubicin—prostate cancer	7.87e-05	0.000118	CcSEcCtD
Acamprosate—Constipation—Epirubicin—prostate cancer	7.87e-05	0.000118	CcSEcCtD
Acamprosate—Nausea—Capecitabine—prostate cancer	7.84e-05	0.000117	CcSEcCtD
Acamprosate—GABRA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—prostate cancer	7.82e-05	0.000278	CbGpPWpGaD
Acamprosate—Dizziness—Prednisone—prostate cancer	7.78e-05	0.000116	CcSEcCtD
Acamprosate—Musculoskeletal discomfort—Doxorubicin—prostate cancer	7.76e-05	0.000116	CcSEcCtD
Acamprosate—GRIN2B—Neuronal System—MDM2—prostate cancer	7.75e-05	0.000276	CbGpPWpGaD
Acamprosate—GRIN2B—Axon guidance—MMP2—prostate cancer	7.74e-05	0.000275	CbGpPWpGaD
Acamprosate—GRIN2B—Axon guidance—MAP2K1—prostate cancer	7.73e-05	0.000275	CbGpPWpGaD
Acamprosate—Insomnia—Doxorubicin—prostate cancer	7.7e-05	0.000115	CcSEcCtD
Acamprosate—GRM5—Signaling Pathways—FGF10—prostate cancer	7.69e-05	0.000274	CbGpPWpGaD
Acamprosate—GABRB3—BDNF signaling pathway—CTNNB1—prostate cancer	7.68e-05	0.000273	CbGpPWpGaD
Acamprosate—GABRA1—Transmembrane transport of small molecules—SLC22A1—prostate cancer	7.67e-05	0.000273	CbGpPWpGaD
Acamprosate—Paraesthesia—Doxorubicin—prostate cancer	7.64e-05	0.000114	CcSEcCtD
Acamprosate—GRM5—Signaling Pathways—ADRB2—prostate cancer	7.61e-05	0.000271	CbGpPWpGaD
Acamprosate—Dyspnoea—Doxorubicin—prostate cancer	7.59e-05	0.000113	CcSEcCtD
Acamprosate—Feeling abnormal—Epirubicin—prostate cancer	7.58e-05	0.000113	CcSEcCtD
Acamprosate—Somnolence—Doxorubicin—prostate cancer	7.57e-05	0.000113	CcSEcCtD
Acamprosate—Gastrointestinal pain—Epirubicin—prostate cancer	7.52e-05	0.000112	CcSEcCtD
Acamprosate—GRM5—GPCR downstream signaling—JAK2—prostate cancer	7.51e-05	0.000267	CbGpPWpGaD
Acamprosate—Dyspepsia—Doxorubicin—prostate cancer	7.49e-05	0.000112	CcSEcCtD
Acamprosate—Vomiting—Prednisone—prostate cancer	7.48e-05	0.000112	CcSEcCtD
Acamprosate—GRM5—Signaling by GPCR—MAP2K1—prostate cancer	7.48e-05	0.000266	CbGpPWpGaD
Acamprosate—GRIN1—Developmental Biology—PPARA—prostate cancer	7.47e-05	0.000266	CbGpPWpGaD
Acamprosate—GRM5—Signaling by GPCR—PIK3CD—prostate cancer	7.43e-05	0.000264	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—VAV3—prostate cancer	7.42e-05	0.000264	CbGpPWpGaD
Acamprosate—Rash—Prednisone—prostate cancer	7.42e-05	0.000111	CcSEcCtD
Acamprosate—Dermatitis—Prednisone—prostate cancer	7.41e-05	0.000111	CcSEcCtD
Acamprosate—Decreased appetite—Doxorubicin—prostate cancer	7.4e-05	0.000111	CcSEcCtD
Acamprosate—Headache—Prednisone—prostate cancer	7.37e-05	0.00011	CcSEcCtD
Acamprosate—Gastrointestinal disorder—Doxorubicin—prostate cancer	7.35e-05	0.00011	CcSEcCtD
Acamprosate—GRM5—Signaling Pathways—TGFBR2—prostate cancer	7.32e-05	0.00026	CbGpPWpGaD
Acamprosate—Urticaria—Epirubicin—prostate cancer	7.31e-05	0.000109	CcSEcCtD
Acamprosate—GABRA1—Transmembrane transport of small molecules—GNG5—prostate cancer	7.29e-05	0.000259	CbGpPWpGaD
Acamprosate—Constipation—Doxorubicin—prostate cancer	7.28e-05	0.000109	CcSEcCtD
Acamprosate—Pain—Doxorubicin—prostate cancer	7.28e-05	0.000109	CcSEcCtD
Acamprosate—GRIN2B—Developmental Biology—PPARA—prostate cancer	7.28e-05	0.000259	CbGpPWpGaD
Acamprosate—Abdominal pain—Epirubicin—prostate cancer	7.27e-05	0.000109	CcSEcCtD
Acamprosate—Body temperature increased—Epirubicin—prostate cancer	7.27e-05	0.000109	CcSEcCtD
Acamprosate—GABRB3—Transmembrane transport of small molecules—PRKACB—prostate cancer	7.24e-05	0.000258	CbGpPWpGaD
Acamprosate—GRIN1—Axon guidance—JAK2—prostate cancer	7.23e-05	0.000257	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—ITPR1—prostate cancer	7.2e-05	0.000256	CbGpPWpGaD
Acamprosate—GRM5—GPCR downstream signaling—PIK3CB—prostate cancer	7.13e-05	0.000254	CbGpPWpGaD
Acamprosate—GABRG2—Transmembrane transport of small molecules—PRKACB—prostate cancer	7.11e-05	0.000253	CbGpPWpGaD
Acamprosate—GRIN1—Developmental Biology—LEP—prostate cancer	7.08e-05	0.000252	CbGpPWpGaD
Acamprosate—GRIN2B—Axon guidance—JAK2—prostate cancer	7.05e-05	0.000251	CbGpPWpGaD
Acamprosate—Feeling abnormal—Doxorubicin—prostate cancer	7.01e-05	0.000105	CcSEcCtD
Acamprosate—Nausea—Prednisone—prostate cancer	6.99e-05	0.000104	CcSEcCtD
Acamprosate—Gastrointestinal pain—Doxorubicin—prostate cancer	6.96e-05	0.000104	CcSEcCtD
Acamprosate—GRIN1—Axon guidance—ERBB2—prostate cancer	6.96e-05	0.000247	CbGpPWpGaD
Acamprosate—GABRB3—BDNF signaling pathway—SRC—prostate cancer	6.94e-05	0.000247	CbGpPWpGaD
Acamprosate—GRIN1—Developmental Biology—KDR—prostate cancer	6.94e-05	0.000247	CbGpPWpGaD
Acamprosate—GRIN2B—Developmental Biology—LEP—prostate cancer	6.91e-05	0.000246	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—IGF1R—prostate cancer	6.88e-05	0.000245	CbGpPWpGaD
Acamprosate—GRM5—GPCR downstream signaling—CXCL8—prostate cancer	6.85e-05	0.000244	CbGpPWpGaD
Acamprosate—GABRB3—Transmission across Chemical Synapses—MDM2—prostate cancer	6.85e-05	0.000244	CbGpPWpGaD
Acamprosate—GABRB3—Transmembrane transport of small molecules—NCOA2—prostate cancer	6.83e-05	0.000243	CbGpPWpGaD
Acamprosate—GRM5—Signaling by GPCR—JAK2—prostate cancer	6.82e-05	0.000243	CbGpPWpGaD
Acamprosate—GRIN2B—Axon guidance—ERBB2—prostate cancer	6.78e-05	0.000241	CbGpPWpGaD
Acamprosate—Hypersensitivity—Epirubicin—prostate cancer	6.78e-05	0.000101	CcSEcCtD
Acamprosate—GRIN2B—Developmental Biology—KDR—prostate cancer	6.77e-05	0.000241	CbGpPWpGaD
Acamprosate—Urticaria—Doxorubicin—prostate cancer	6.76e-05	0.000101	CcSEcCtD
Acamprosate—Abdominal pain—Doxorubicin—prostate cancer	6.73e-05	0.000101	CcSEcCtD
Acamprosate—Body temperature increased—Doxorubicin—prostate cancer	6.73e-05	0.000101	CcSEcCtD
Acamprosate—GABRG2—Transmission across Chemical Synapses—MDM2—prostate cancer	6.72e-05	0.000239	CbGpPWpGaD
Acamprosate—GABRG2—Transmembrane transport of small molecules—NCOA2—prostate cancer	6.71e-05	0.000239	CbGpPWpGaD
Acamprosate—GABRA1—SIDS Susceptibility Pathways—CXCL8—prostate cancer	6.7e-05	0.000238	CbGpPWpGaD
Acamprosate—GABRB3—BDNF signaling pathway—STAT3—prostate cancer	6.7e-05	0.000238	CbGpPWpGaD
Acamprosate—GRIN1—SIDS Susceptibility Pathways—IL6—prostate cancer	6.65e-05	0.000237	CbGpPWpGaD
Acamprosate—Asthenia—Epirubicin—prostate cancer	6.6e-05	9.87e-05	CcSEcCtD
Acamprosate—GRM5—Signaling Pathways—LPL—prostate cancer	6.6e-05	0.000235	CbGpPWpGaD
Acamprosate—GRM5—GPCR downstream signaling—IL2—prostate cancer	6.55e-05	0.000233	CbGpPWpGaD
Acamprosate—GRIN1—BDNF signaling pathway—AKT1—prostate cancer	6.54e-05	0.000233	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—PDGFRB—prostate cancer	6.54e-05	0.000233	CbGpPWpGaD
Acamprosate—GABRB3—Transmembrane transport of small molecules—SLC5A5—prostate cancer	6.52e-05	0.000232	CbGpPWpGaD
Acamprosate—Pruritus—Epirubicin—prostate cancer	6.51e-05	9.73e-05	CcSEcCtD
Acamprosate—GRM5—Signaling by GPCR—PIK3CB—prostate cancer	6.47e-05	0.00023	CbGpPWpGaD
Acamprosate—GABRA1—SIDS Susceptibility Pathways—CASP3—prostate cancer	6.42e-05	0.000228	CbGpPWpGaD
Acamprosate—GABRG2—Transmembrane transport of small molecules—SLC5A5—prostate cancer	6.4e-05	0.000228	CbGpPWpGaD
Acamprosate—GRIN2B—BDNF signaling pathway—AKT1—prostate cancer	6.38e-05	0.000227	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—ITGB3—prostate cancer	6.37e-05	0.000227	CbGpPWpGaD
Acamprosate—Diarrhoea—Epirubicin—prostate cancer	6.29e-05	9.41e-05	CcSEcCtD
Acamprosate—Hypersensitivity—Doxorubicin—prostate cancer	6.27e-05	9.38e-05	CcSEcCtD
Acamprosate—GRM5—Signaling by GPCR—CXCL8—prostate cancer	6.22e-05	0.000221	CbGpPWpGaD
Acamprosate—GABRA1—Transmembrane transport of small molecules—PRKACB—prostate cancer	6.22e-05	0.000221	CbGpPWpGaD
Acamprosate—GABRA1—SIDS Susceptibility Pathways—CTNNB1—prostate cancer	6.18e-05	0.00022	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—ERBB3—prostate cancer	6.18e-05	0.00022	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—FGFR2—prostate cancer	6.17e-05	0.00022	CbGpPWpGaD
Acamprosate—GRIN1—Developmental Biology—GSK3B—prostate cancer	6.13e-05	0.000218	CbGpPWpGaD
Acamprosate—Asthenia—Doxorubicin—prostate cancer	6.11e-05	9.13e-05	CcSEcCtD
Acamprosate—Dizziness—Epirubicin—prostate cancer	6.08e-05	9.1e-05	CcSEcCtD
Acamprosate—GRIN1—Developmental Biology—INS—prostate cancer	6.05e-05	0.000215	CbGpPWpGaD
Acamprosate—Pruritus—Doxorubicin—prostate cancer	6.02e-05	9e-05	CcSEcCtD
Acamprosate—GRIN2B—Developmental Biology—GSK3B—prostate cancer	5.98e-05	0.000213	CbGpPWpGaD
Acamprosate—GRIN1—Axon guidance—MMP9—prostate cancer	5.97e-05	0.000212	CbGpPWpGaD
Acamprosate—GRM5—Signaling by GPCR—IL2—prostate cancer	5.95e-05	0.000212	CbGpPWpGaD
Acamprosate—GRIN1—Developmental Biology—CREBBP—prostate cancer	5.93e-05	0.000211	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—TERT—prostate cancer	5.92e-05	0.000211	CbGpPWpGaD
Acamprosate—GRIN2B—Developmental Biology—INS—prostate cancer	5.9e-05	0.00021	CbGpPWpGaD
Acamprosate—GABRA1—Transmission across Chemical Synapses—MDM2—prostate cancer	5.88e-05	0.000209	CbGpPWpGaD
Acamprosate—GABRA1—Transmembrane transport of small molecules—NCOA2—prostate cancer	5.86e-05	0.000209	CbGpPWpGaD
Acamprosate—Vomiting—Epirubicin—prostate cancer	5.85e-05	8.75e-05	CcSEcCtD
Acamprosate—Diarrhoea—Doxorubicin—prostate cancer	5.82e-05	8.71e-05	CcSEcCtD
Acamprosate—GRIN2B—Axon guidance—MMP9—prostate cancer	5.82e-05	0.000207	CbGpPWpGaD
Acamprosate—Rash—Epirubicin—prostate cancer	5.8e-05	8.67e-05	CcSEcCtD
Acamprosate—Dermatitis—Epirubicin—prostate cancer	5.8e-05	8.66e-05	CcSEcCtD
Acamprosate—GRIN2B—Developmental Biology—CREBBP—prostate cancer	5.78e-05	0.000206	CbGpPWpGaD
Acamprosate—Headache—Epirubicin—prostate cancer	5.76e-05	8.62e-05	CcSEcCtD
Acamprosate—GABRB3—Transmembrane transport of small molecules—NCOA1—prostate cancer	5.76e-05	0.000205	CbGpPWpGaD
Acamprosate—GABRA1—SIDS Susceptibility Pathways—EP300—prostate cancer	5.75e-05	0.000204	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—HIF1A—prostate cancer	5.67e-05	0.000202	CbGpPWpGaD
Acamprosate—GRIN1—Developmental Biology—MMP2—prostate cancer	5.66e-05	0.000202	CbGpPWpGaD
Acamprosate—GRIN1—Developmental Biology—MAP2K1—prostate cancer	5.66e-05	0.000201	CbGpPWpGaD
Acamprosate—GABRG2—Transmembrane transport of small molecules—NCOA1—prostate cancer	5.65e-05	0.000201	CbGpPWpGaD
Acamprosate—Dizziness—Doxorubicin—prostate cancer	5.63e-05	8.42e-05	CcSEcCtD
Acamprosate—GABRA1—Transmembrane transport of small molecules—SLC5A5—prostate cancer	5.59e-05	0.000199	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—LEP—prostate cancer	5.53e-05	0.000197	CbGpPWpGaD
Acamprosate—GRIN2B—Developmental Biology—MMP2—prostate cancer	5.52e-05	0.000196	CbGpPWpGaD
Acamprosate—GRIN2B—Developmental Biology—MAP2K1—prostate cancer	5.52e-05	0.000196	CbGpPWpGaD
Acamprosate—GRIN1—Axon guidance—SRC—prostate cancer	5.5e-05	0.000196	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—CAV1—prostate cancer	5.48e-05	0.000195	CbGpPWpGaD
Acamprosate—GABRB3—Transmembrane transport of small molecules—RXRA—prostate cancer	5.47e-05	0.000195	CbGpPWpGaD
Acamprosate—Nausea—Epirubicin—prostate cancer	5.46e-05	8.17e-05	CcSEcCtD
Acamprosate—GABRA1—SIDS Susceptibility Pathways—VEGFA—prostate cancer	5.44e-05	0.000194	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—KDR—prostate cancer	5.42e-05	0.000193	CbGpPWpGaD
Acamprosate—Vomiting—Doxorubicin—prostate cancer	5.41e-05	8.09e-05	CcSEcCtD
Acamprosate—GRIN1—Developmental Biology—FGF2—prostate cancer	5.38e-05	0.000191	CbGpPWpGaD
Acamprosate—GABRG2—Transmembrane transport of small molecules—RXRA—prostate cancer	5.38e-05	0.000191	CbGpPWpGaD
Acamprosate—Rash—Doxorubicin—prostate cancer	5.37e-05	8.02e-05	CcSEcCtD
Acamprosate—GRIN2B—Axon guidance—SRC—prostate cancer	5.36e-05	0.000191	CbGpPWpGaD
Acamprosate—Dermatitis—Doxorubicin—prostate cancer	5.36e-05	8.02e-05	CcSEcCtD
Acamprosate—GRIN1—Axon guidance—VEGFA—prostate cancer	5.36e-05	0.000191	CbGpPWpGaD
Acamprosate—Headache—Doxorubicin—prostate cancer	5.33e-05	7.97e-05	CcSEcCtD
Acamprosate—GRM5—Signaling Pathways—ESR1—prostate cancer	5.28e-05	0.000188	CbGpPWpGaD
Acamprosate—GABRB3—Neuronal System—MDM2—prostate cancer	5.25e-05	0.000187	CbGpPWpGaD
Acamprosate—GRIN2B—Developmental Biology—FGF2—prostate cancer	5.25e-05	0.000187	CbGpPWpGaD
Acamprosate—GRIN2B—Axon guidance—VEGFA—prostate cancer	5.22e-05	0.000186	CbGpPWpGaD
Acamprosate—GRIN1—Developmental Biology—JAK2—prostate cancer	5.16e-05	0.000183	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—BAD—prostate cancer	5.15e-05	0.000183	CbGpPWpGaD
Acamprosate—GABRG2—Neuronal System—MDM2—prostate cancer	5.15e-05	0.000183	CbGpPWpGaD
Acamprosate—Nausea—Doxorubicin—prostate cancer	5.06e-05	7.56e-05	CcSEcCtD
Acamprosate—GRIN2B—Developmental Biology—JAK2—prostate cancer	5.03e-05	0.000179	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—APC—prostate cancer	4.99e-05	0.000178	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—PIK3CG—prostate cancer	4.99e-05	0.000178	CbGpPWpGaD
Acamprosate—GRIN1—Developmental Biology—ERBB2—prostate cancer	4.96e-05	0.000177	CbGpPWpGaD
Acamprosate—GABRA1—Transmembrane transport of small molecules—NCOA1—prostate cancer	4.94e-05	0.000176	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—EGF—prostate cancer	4.93e-05	0.000176	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—IRS1—prostate cancer	4.93e-05	0.000176	CbGpPWpGaD
Acamprosate—GRIN2B—Developmental Biology—ERBB2—prostate cancer	4.84e-05	0.000172	CbGpPWpGaD
Acamprosate—GRIN1—Axon guidance—EGFR—prostate cancer	4.82e-05	0.000172	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—GSK3B—prostate cancer	4.79e-05	0.00017	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—INS—prostate cancer	4.72e-05	0.000168	CbGpPWpGaD
Acamprosate—GRIN2B—Axon guidance—EGFR—prostate cancer	4.7e-05	0.000167	CbGpPWpGaD
Acamprosate—GABRA1—Transmembrane transport of small molecules—RXRA—prostate cancer	4.7e-05	0.000167	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—CREBBP—prostate cancer	4.63e-05	0.000165	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—IGF1—prostate cancer	4.57e-05	0.000163	CbGpPWpGaD
Acamprosate—GRIN1—Axon guidance—KRAS—prostate cancer	4.55e-05	0.000162	CbGpPWpGaD
Acamprosate—GRM5—Signaling by GPCR—EGFR—prostate cancer	4.55e-05	0.000162	CbGpPWpGaD
Acamprosate—GABRA1—Neuronal System—MDM2—prostate cancer	4.5e-05	0.00016	CbGpPWpGaD
Acamprosate—GRIN2B—Axon guidance—KRAS—prostate cancer	4.44e-05	0.000158	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—MAP2K1—prostate cancer	4.42e-05	0.000157	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—PIK3CD—prostate cancer	4.39e-05	0.000156	CbGpPWpGaD
Acamprosate—GRM5—GPCR downstream signaling—PIK3CA—prostate cancer	4.35e-05	0.000155	CbGpPWpGaD
Acamprosate—GRIN1—Developmental Biology—CTNNB1—prostate cancer	4.34e-05	0.000155	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—SERPINE1—prostate cancer	4.34e-05	0.000154	CbGpPWpGaD
Acamprosate—GABRB3—BDNF signaling pathway—AKT1—prostate cancer	4.31e-05	0.000153	CbGpPWpGaD
Acamprosate—GRM5—Signaling by GPCR—KRAS—prostate cancer	4.3e-05	0.000153	CbGpPWpGaD
Acamprosate—GRIN1—Developmental Biology—MMP9—prostate cancer	4.26e-05	0.000151	CbGpPWpGaD
Acamprosate—GRIN2B—Developmental Biology—CTNNB1—prostate cancer	4.23e-05	0.000151	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—FGF2—prostate cancer	4.2e-05	0.000149	CbGpPWpGaD
Acamprosate—GABRB3—Transmembrane transport of small molecules—PPARA—prostate cancer	4.18e-05	0.000149	CbGpPWpGaD
Acamprosate—GRIN2B—Developmental Biology—MMP9—prostate cancer	4.15e-05	0.000148	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—NOS3—prostate cancer	4.14e-05	0.000147	CbGpPWpGaD
Acamprosate—GABRG2—Transmembrane transport of small molecules—PPARA—prostate cancer	4.11e-05	0.000146	CbGpPWpGaD
Acamprosate—GRIN1—Developmental Biology—EP300—prostate cancer	4.04e-05	0.000144	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—JAK2—prostate cancer	4.03e-05	0.000143	CbGpPWpGaD
Acamprosate—GRM5—Signaling by GPCR—PIK3CA—prostate cancer	3.95e-05	0.00014	CbGpPWpGaD
Acamprosate—GRIN2B—Developmental Biology—EP300—prostate cancer	3.94e-05	0.00014	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—MDM2—prostate cancer	3.93e-05	0.00014	CbGpPWpGaD
Acamprosate—GRIN1—Developmental Biology—SRC—prostate cancer	3.93e-05	0.00014	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—ERBB2—prostate cancer	3.88e-05	0.000138	CbGpPWpGaD
Acamprosate—GRIN2B—Developmental Biology—SRC—prostate cancer	3.83e-05	0.000136	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—PIK3CB—prostate cancer	3.82e-05	0.000136	CbGpPWpGaD
Acamprosate—GRIN1—Developmental Biology—VEGFA—prostate cancer	3.82e-05	0.000136	CbGpPWpGaD
Acamprosate—GRIN1—Developmental Biology—STAT3—prostate cancer	3.79e-05	0.000135	CbGpPWpGaD
Acamprosate—GABRA1—SIDS Susceptibility Pathways—IL6—prostate cancer	3.77e-05	0.000134	CbGpPWpGaD
Acamprosate—GRIN2B—Developmental Biology—VEGFA—prostate cancer	3.73e-05	0.000133	CbGpPWpGaD
Acamprosate—GRIN1—Axon guidance—IL6—prostate cancer	3.71e-05	0.000132	CbGpPWpGaD
Acamprosate—GRIN2B—Developmental Biology—STAT3—prostate cancer	3.69e-05	0.000131	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—CXCL8—prostate cancer	3.68e-05	0.000131	CbGpPWpGaD
Acamprosate—GRIN2B—Axon guidance—IL6—prostate cancer	3.61e-05	0.000129	CbGpPWpGaD
Acamprosate—GABRA1—Transmembrane transport of small molecules—PPARA—prostate cancer	3.59e-05	0.000128	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—CDKN1B—prostate cancer	3.59e-05	0.000128	CbGpPWpGaD
Acamprosate—GRM5—GPCR downstream signaling—AKT1—prostate cancer	3.55e-05	0.000126	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—CASP3—prostate cancer	3.52e-05	0.000125	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—IL2—prostate cancer	3.51e-05	0.000125	CbGpPWpGaD
Acamprosate—GRIN1—Developmental Biology—TGFB1—prostate cancer	3.51e-05	0.000125	CbGpPWpGaD
Acamprosate—GRM5—Signaling by GPCR—IL6—prostate cancer	3.49e-05	0.000124	CbGpPWpGaD
Acamprosate—GRIN1—Developmental Biology—EGFR—prostate cancer	3.44e-05	0.000122	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—CCND1—prostate cancer	3.42e-05	0.000122	CbGpPWpGaD
Acamprosate—GRIN2B—Developmental Biology—TGFB1—prostate cancer	3.42e-05	0.000122	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—CTNNB1—prostate cancer	3.39e-05	0.000121	CbGpPWpGaD
Acamprosate—GRIN2B—Developmental Biology—EGFR—prostate cancer	3.35e-05	0.000119	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—MMP9—prostate cancer	3.32e-05	0.000118	CbGpPWpGaD
Acamprosate—GABRB3—Transmembrane transport of small molecules—CREBBP—prostate cancer	3.32e-05	0.000118	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—CDKN1A—prostate cancer	3.31e-05	0.000118	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—PTEN—prostate cancer	3.3e-05	0.000118	CbGpPWpGaD
Acamprosate—GABRG2—Transmembrane transport of small molecules—CREBBP—prostate cancer	3.26e-05	0.000116	CbGpPWpGaD
Acamprosate—GRIN1—Developmental Biology—KRAS—prostate cancer	3.25e-05	0.000116	CbGpPWpGaD
Acamprosate—GRM5—Signaling by GPCR—AKT1—prostate cancer	3.22e-05	0.000115	CbGpPWpGaD
Acamprosate—GRIN2B—Developmental Biology—KRAS—prostate cancer	3.17e-05	0.000113	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—EP300—prostate cancer	3.15e-05	0.000112	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—SRC—prostate cancer	3.06e-05	0.000109	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—VEGFA—prostate cancer	2.99e-05	0.000106	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—STAT3—prostate cancer	2.96e-05	0.000105	CbGpPWpGaD
Acamprosate—GABRA1—Transmembrane transport of small molecules—CREBBP—prostate cancer	2.85e-05	0.000101	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—MYC—prostate cancer	2.75e-05	9.77e-05	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—TGFB1—prostate cancer	2.74e-05	9.75e-05	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—EGFR—prostate cancer	2.69e-05	9.56e-05	CbGpPWpGaD
Acamprosate—GRIN1—Developmental Biology—IL6—prostate cancer	2.64e-05	9.41e-05	CbGpPWpGaD
Acamprosate—GRIN2B—Developmental Biology—IL6—prostate cancer	2.58e-05	9.17e-05	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—KRAS—prostate cancer	2.54e-05	9.03e-05	CbGpPWpGaD
Acamprosate—GRIN1—Developmental Biology—AKT1—prostate cancer	2.44e-05	8.68e-05	CbGpPWpGaD
Acamprosate—GRIN2B—Developmental Biology—AKT1—prostate cancer	2.38e-05	8.46e-05	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—PIK3CA—prostate cancer	2.33e-05	8.29e-05	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—TP53—prostate cancer	2.26e-05	8.02e-05	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—IL6—prostate cancer	2.06e-05	7.35e-05	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—AKT1—prostate cancer	1.9e-05	6.78e-05	CbGpPWpGaD
